Valuation
- Market cap
- 801,769,000
- Revenue TTM
- $60,000
- Net income TTM
- $-78,260,000
- PE ratio
- 0.00
- Forward PE
- —
- Profit margin
- -130,433.34%
- Debt to equity
- 0.00
Trading
- Volume
- 948,500
- Avg volume
- 946,228
- Day's range
- $14.31 – $15.16
- Shares out
- 53,630,000
- Stochastic %K
- 27%
- Beta
- 0.68
- Analysts
- Strong Sell
- Price target
- $44.08
Company profile
Avalo Therapeutics, Inc., a clinical stage biotechnology company, develops IL-1ß-based treatments for immune-mediated inflammatory diseases in the Unites States. Its lead product includes AVTX-009, a humanized monoclonal antibody that binds to interleukin-1ß, which is in phase 2 clinical trial to treat inflammatory diseases. The company was formerly known as Cerecor Inc. and changed its name to Avalo Therapeutics, In...
Show more
Avalo Therapeutics, Inc., a clinical stage biotechnology company, develops IL-1ß-based treatments for immune-mediated inflammatory diseases in the Unites States. Its lead product includes AVTX-009, a humanized monoclonal antibody that binds to interleukin-1ß, which is in phase 2 clinical trial to treat inflammatory diseases. The company was formerly known as Cerecor Inc. and changed its name to Avalo Therapeutics, Inc. in August 2021. Avalo Therapeutics, Inc. was incorporated in 2011 and is headquartered in Wayne, Pennsylvania.
- Industry
- Biotechnology
- Sector
- Healthcare
- Phone
- 410 522 8707
- Website
- https://www.avalotx.com
- Address
- 1500 Liberty Ridge Drive, Suite 321, Wayne, United States
Latest news
No headlines yet.
